We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ortho-McNeil Neurologics has updated prescribing information on its Alzheimer's
drug Reminyl to disclose recent deaths among patients participating in two clinical
trials of the drug, according to an FDA MedWatch report.
In a major win for Toronto-based biotechnology company
Biovail, a U.S. district court has granted the company's request for summary
judgment in two related class-action lawsuits involving the company's hypertension
and angina medication, Tiazac.
Sentrx has completed an FDA electronic submissions pilot and has begun sending
individual case safety reports from a leading pharmaceutical company to the
agency through the Electronic Standards for the Transmission of Regulatory Information
(ESTRI) Gateway, the technology company said.
A bill recently introduced in the House would significantly curtail the times
that drugmakers could promote erectile dysfunction (ED) products over the airwaves
-- a proposal that may indicate a growing discontent with the pharmaceutical
industry's use of direct-to-consumer (DTC) advertising.
Dendrite International, a leading provider of sales,
marketing and clinical solutions for the life science and pharmaceutical industries,
announced that it signed a comprehensive, five-year software and services agreement
with the sanofi-aventis Group in the U.S., the third largest pharmaceutical
company in the world and the largest in Europe.
The law firm of Kenneth B. Moll & Associates filed the first worldwide class
action lawsuit against Pfizer, on behalf of all persons who died or were injured
by the pain medication, Bextra.
Innovate Oncology, a company founded by Bioaccelerate Holdings, announced that
it has entered into an exclusive agreement with Prostagenics, acquiring the
rights to develop and commercialize Capridine-Beta for the treatment of prostate
cancer.
Reliant Pharmaceuticals, Inc. announced that the term of the promotion agreement
with Novartis for Lescol (fluvastatin sodium) and Lescol XL (fluvastatin sodium
extended-release tablets) will be extended.
CellCentric, a Cambridge company exploiting a critical area of genetic research,
has won £250,000 funding that has triggered a commercial collaboration
with Babraham Institute.
Diversa Corporation announced that it has signed an agreement with Cargill Health
and Food Technologies to discover and develop novel enzymes for the cost-effective
production of a proprietary product.
Private biopharmaceutical firm, VasoGenix Pharmaceuticals, has signed a worldwide
agreement with QLT USA Inc. to develop a potentially major new treatment for
congestive heart failure.